Self-monitoring of Blood Pressure in Patients With Hypertension-Related Multi-morbidity: Systematic Review and Individual Patient Data Meta-analysis.


Journal

American journal of hypertension
ISSN: 1941-7225
Titre abrégé: Am J Hypertens
Pays: United States
ID NLM: 8803676

Informations de publication

Date de publication:
13 03 2020
Historique:
received: 04 10 2019
revised: 11 11 2019
accepted: 13 11 2019
pubmed: 16 11 2019
medline: 16 12 2020
entrez: 16 11 2019
Statut: ppublish

Résumé

Studies have shown that self-monitoring of blood pressure (BP) is effective when combined with co-interventions, but its efficacy varies in the presence of some co-morbidities. This study examined whether self-monitoring can reduce clinic BP in patients with hypertension-related co-morbidity. A systematic review was conducted of articles published in Medline, Embase, and the Cochrane Library up to January 2018. Randomized controlled trials of self-monitoring of BP were selected and individual patient data (IPD) were requested. Contributing studies were prospectively categorized by whether they examined a low/high-intensity co-intervention. Change in BP and likelihood of uncontrolled BP at 12 months were examined according to number and type of hypertension-related co-morbidity in a one-stage IPD meta-analysis. A total of 22 trials were eligible, 16 of which were able to provide IPD for the primary outcome, including 6,522 (89%) participants with follow-up data. Self-monitoring was associated with reduced clinic systolic BP compared to usual care at 12-month follow-up, regardless of the number of hypertension-related co-morbidities (-3.12 mm Hg, [95% confidence intervals -4.78, -1.46 mm Hg]; P value for interaction with number of morbidities = 0.260). Intense interventions were more effective than low-intensity interventions in patients with obesity (P < 0.001 for all outcomes), and possibly stroke (P < 0.004 for BP control outcome only), but this effect was not observed in patients with coronary heart disease, diabetes, or chronic kidney disease. Self-monitoring lowers BP regardless of the number of hypertension-related co-morbidities, but may only be effective in conditions such obesity or stroke when combined with high-intensity co-interventions.

Sections du résumé

BACKGROUND
Studies have shown that self-monitoring of blood pressure (BP) is effective when combined with co-interventions, but its efficacy varies in the presence of some co-morbidities. This study examined whether self-monitoring can reduce clinic BP in patients with hypertension-related co-morbidity.
METHODS
A systematic review was conducted of articles published in Medline, Embase, and the Cochrane Library up to January 2018. Randomized controlled trials of self-monitoring of BP were selected and individual patient data (IPD) were requested. Contributing studies were prospectively categorized by whether they examined a low/high-intensity co-intervention. Change in BP and likelihood of uncontrolled BP at 12 months were examined according to number and type of hypertension-related co-morbidity in a one-stage IPD meta-analysis.
RESULTS
A total of 22 trials were eligible, 16 of which were able to provide IPD for the primary outcome, including 6,522 (89%) participants with follow-up data. Self-monitoring was associated with reduced clinic systolic BP compared to usual care at 12-month follow-up, regardless of the number of hypertension-related co-morbidities (-3.12 mm Hg, [95% confidence intervals -4.78, -1.46 mm Hg]; P value for interaction with number of morbidities = 0.260). Intense interventions were more effective than low-intensity interventions in patients with obesity (P < 0.001 for all outcomes), and possibly stroke (P < 0.004 for BP control outcome only), but this effect was not observed in patients with coronary heart disease, diabetes, or chronic kidney disease.
CONCLUSIONS
Self-monitoring lowers BP regardless of the number of hypertension-related co-morbidities, but may only be effective in conditions such obesity or stroke when combined with high-intensity co-interventions.

Identifiants

pubmed: 31730171
pii: 5626378
doi: 10.1093/ajh/hpz182
pmc: PMC7162426
doi:

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

243-251

Subventions

Organisme : Department of Health
ID : NIHR-RP-02-12-015
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 211182/Z/18/Z
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : R01 HL070713
Pays : United States
Organisme : HSRD VA
ID : IK6 HX003161
Pays : United States
Organisme : Chief Scientist Office
ID : ARPG/07/03
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : R01 HL090965
Pays : United States

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd.

Références

CMAJ. 2013 Jan 8;185(1):23-31
pubmed: 23128283
Ann Intern Med. 2009 Nov 17;151(10):687-95
pubmed: 19920269
Ann Intern Med. 2013 Aug 6;159(3):185-94
pubmed: 23922064
J Clin Pharm Ther. 2014 Oct;39(5):527-34
pubmed: 24943987
Med Care. 1999 Jan;37(1):5-14
pubmed: 10413387
Circ Cardiovasc Qual Outcomes. 2013 Mar 1;6(2):157-63
pubmed: 23463811
JAMA. 2013 Jul 3;310(1):46-56
pubmed: 23821088
N Engl J Med. 2010 Dec 30;363(27):2611-20
pubmed: 21190455
Evid Based Med. 2011 Feb;16(1):17-8
pubmed: 21109677
PLoS Med. 2017 Sep 19;14(9):e1002389
pubmed: 28926573
J Hypertens. 2009 Jan;27(1):198-203
pubmed: 19145785
Lancet. 2010 Jul 17;376(9736):163-72
pubmed: 20619448
Contemp Clin Trials. 2008 May;29(3):376-95
pubmed: 17974502
BMJ. 2005 Sep 3;331(7515):493
pubmed: 16115830
Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006560
pubmed: 22513941
Trials. 2013 Jan 23;14:22
pubmed: 23343138
Lancet. 2012 Jul 7;380(9836):37-43
pubmed: 22579043
Am J Hypertens. 2005 Nov;18(11):1415-20
pubmed: 16280273
J Am Board Fam Med. 2013 Sep-Oct;26(5):518-24
pubmed: 24004703
Telemed J E Health. 2011 May;17(4):254-61
pubmed: 21476945
Fam Pract. 2010 Apr;27(2):135-42
pubmed: 20032170
Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2):138-45
pubmed: 25737487
Am Heart J. 2013 Apr;165(4):615-21
pubmed: 23537980
Patient Prefer Adherence. 2014 Dec 05;8:1683-90
pubmed: 25525344
BMC Med. 2014 Oct 23;12:188
pubmed: 25338506
Lancet. 2002 Dec 14;360(9349):1903-13
pubmed: 12493255
Health Qual Life Outcomes. 2004 Sep 20;2:51
pubmed: 15380021
Diabetes Obes Metab. 2016 Apr;18(4):401-9
pubmed: 26743666
J Prim Care Community Health. 2016 Apr;7(2):58-64
pubmed: 26574566
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Syst Rev. 2018 Jun 13;7(1):84
pubmed: 29898785
Health Qual Life Outcomes. 2017 Jan 9;15(1):7
pubmed: 28069026
J Gen Intern Med. 2012 Jun;27(6):630-9
pubmed: 22143452
Am Heart J. 2007 Jun;153(6):918-24
pubmed: 17540191
Cochrane Database Syst Rev. 2018 May 07;5:CD009103
pubmed: 29734470
Circulation. 2014 May 20;129(20):2044-51
pubmed: 24657991
BMJ. 2013 May 24;346:f3030
pubmed: 23709583
BMC Public Health. 2014 May 29;14:530
pubmed: 24885174
BMJ Open. 2015 Sep 15;5(9):e008532
pubmed: 26373404
Fam Pract. 2015 Jun;32(3):311-6
pubmed: 25715962
JAMA. 2014 Aug 27;312(8):799-808
pubmed: 25157723
Am J Hypertens. 2007 Dec;20(12):1258-65
pubmed: 18047914
JAMA Intern Med. 2014 May;174(5):818-9
pubmed: 24615061
Am J Prev Med. 2014 Apr;46(4):368-77
pubmed: 24650839
Ann Med. 2010 Jul;42(5):371-86
pubmed: 20504241

Auteurs

J P Sheppard (JP)

Nuffield Department of Primary Care, University of Oxford, Oxford, United Kingdom.

K L Tucker (KL)

Nuffield Department of Primary Care, University of Oxford, Oxford, United Kingdom.

W J Davison (WJ)

Ageing and Stroke Medicine, Norwich Medical School, University of East Anglia, United Kingdom.

R Stevens (R)

Nuffield Department of Primary Care, University of Oxford, Oxford, United Kingdom.

W Aekplakorn (W)

Department of Community Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University Bangkok, Thailand.

H B Bosworth (HB)

Center for Health Services Research in Primary Care, Department of Population Health Sciences, Duke University, Durham, North Carolina, USA.

A Bove (A)

Cardiology, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.

K Earle (K)

Thomas Addison Diabetes Unit, St. George's University Hospitals NHS Foundation Trust, London, United Kingdom.

M Godwin (M)

Family Medicine, Memorial University of Newfoundland, St. John's, Canada.

B B Green (BB)

Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.

P Hebert (P)

Department of Health Services, University of Washington School of Public Health, Seattle, Washington, USA.

C Heneghan (C)

Nuffield Department of Primary Care, University of Oxford, Oxford, United Kingdom.

N Hill (N)

Nuffield Department of Primary Care, University of Oxford, Oxford, United Kingdom.

F D R Hobbs (FDR)

Nuffield Department of Primary Care, University of Oxford, Oxford, United Kingdom.

I Kantola (I)

Division of Medicine, Turku University Hospital and University of Turku, Turku, Finland.

S M Kerry (SM)

Centre for Primary Care and Public Health, Queen Mary University of London, London, United Kingdom.

A Leiva (A)

Primary Care Research Unit of Mallorca, Baleares Health Services-IbSalut, Mallorca, Spain.

D J Magid (DJ)

Colorado School of Public Health, University of Colorado, Denver, Colorado, USA.

J Mant (J)

Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.

K L Margolis (KL)

HealthPartners Institute, Minneapolis, Minnesota, USA.

B McKinstry (B)

Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom.

M A McLaughlin (MA)

Icahn School of Medicine at Mount Sinai New York, New York, New York, USA.

K McNamara (K)

Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia.
School of Medicine, Deakin University, Geelong, Australia.

S Omboni (S)

Clinical Research Unit, Italian Institute of Telemedicine, Varese, Italy.
Scientific Research Department of Cardiology, Science and Technology Park for Biomedicine, Sechenov First Moscow State Medical University, Moscow, Russian Federation.

O Ogedegbe (O)

Center for Healthful Behavior Change, Division of Health and Behavior, Department of Population Health, Langone School of Medicine, New York University, New York, USA.

G Parati (G)

Istituto Auxologico Italiano, IRCCS, Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, Milan, Italy.
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.

J Varis (J)

Division of Medicine, Turku University Hospital and University of Turku, Turku, Finland.

W J Verberk (WJ)

Cardiovascular Research Institute Maastricht and Departments of Internal Medicine, Maastricht University, Maastricht, The Netherlands.

B J Wakefield (BJ)

Department of Veterans (VA) Health Services Research and Development Centre for Comprehensive Access and Delivery Research and Evaluation (CADRE), VA Medical Centre, Iowa City, USA.

R J McManus (RJ)

Nuffield Department of Primary Care, University of Oxford, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH